Artivion Inc (AORT) 주가 예측

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. The company has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.